ES2196157T3 - Oligonucleotidos especificos para el virus de la hepatitis c. - Google Patents

Oligonucleotidos especificos para el virus de la hepatitis c.

Info

Publication number
ES2196157T3
ES2196157T3 ES96920788T ES96920788T ES2196157T3 ES 2196157 T3 ES2196157 T3 ES 2196157T3 ES 96920788 T ES96920788 T ES 96920788T ES 96920788 T ES96920788 T ES 96920788T ES 2196157 T3 ES2196157 T3 ES 2196157T3
Authority
ES
Spain
Prior art keywords
hcv
hepatitis
virus
specific oligonucleotides
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920788T
Other languages
English (en)
Inventor
Bruce L Frank
John Goodchild
Henry A Hamlin Jr
Robert E Kilkuskie
Noel A Roberts
Peter C Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ES2196157T3 publication Critical patent/ES2196157T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION PRESENTA OLIGONUCLEOTIDOS SINTETICOS COMPLEMENTARIOS A LAS REGIONES CONTIGUA Y NO CONTIGUA DEL ARN DEL VHC. TAMBIEN SE PRESENTAN LOS METODOS Y EQUIPOS DE ANALISIS PARA INHIBIR LA REPLICACION DEL VHC, INHIBIR LA EXPRESION DEL ACIDO NUCLEICO Y PROTEINAS DEL VHC Y TRATAR LAS INFECCIONES POR VHC.
ES96920788T 1995-06-06 1996-06-04 Oligonucleotidos especificos para el virus de la hepatitis c. Expired - Lifetime ES2196157T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47196895A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
ES2196157T3 true ES2196157T3 (es) 2003-12-16

Family

ID=23873702

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920788T Expired - Lifetime ES2196157T3 (es) 1995-06-06 1996-06-04 Oligonucleotidos especificos para el virus de la hepatitis c.

Country Status (10)

Country Link
EP (2) EP1331267A3 (es)
AR (1) AR002757A1 (es)
AT (1) ATE240392T1 (es)
AU (1) AU6221996A (es)
CA (1) CA2226438A1 (es)
DE (1) DE69628167D1 (es)
ES (1) ES2196157T3 (es)
PT (1) PT833902E (es)
WO (1) WO1996039500A2 (es)
ZA (1) ZA964446B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097991A1 (es) * 2004-03-25 2005-10-20 Consejo Superior De Investigaciones Científicas Secuencia de rna, construcción de rna y dna, y composición farmacéutica inhibidoras de la proliferación del virus causante de la hepatitis tipo c (vhc), y sus aplicaciones

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002878A3 (en) * 1998-11-19 2003-11-12 Tosoh Corporation Hepatitis C Virus RNA-binding oligo DNA and method preparing it
EP1867718B1 (en) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
RU2413520C2 (ru) * 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
US6586584B2 (en) 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
US20030059443A1 (en) * 2001-08-22 2003-03-27 Ecker David J. Molecular interaction sites of hepatitis C virus RNA and methods of modulating the same
FR2884522A1 (fr) * 2005-04-19 2006-10-20 Larissa Balakireva Methode d'inhibition de la traduction et/ou la replication d'une sequence d'arn par multimerisation d'une de ses regions d'arn non codant replie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
EP0662128B1 (en) * 1992-09-28 2005-11-23 Chiron Corporation Methods and compositions for controlling translation of hcv proteins
WO1995030746A1 (en) * 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097991A1 (es) * 2004-03-25 2005-10-20 Consejo Superior De Investigaciones Científicas Secuencia de rna, construcción de rna y dna, y composición farmacéutica inhibidoras de la proliferación del virus causante de la hepatitis tipo c (vhc), y sus aplicaciones
ES2270656A1 (es) * 2004-03-25 2007-04-01 Consejo Sup. Investig. Cientificas Secuencia de rna, construccion de rna y dna, y composicion farmaceutica inhibidoras de la proliferacion del virus causante de la hepatitis tipo c (vhc), y sus aplicaciones.
ES2270656B1 (es) * 2004-03-25 2008-03-16 Consejo Sup. Investig. Cientificas Secuencia de rna, construccion de rna y dna, y composicion farmaceutica inhibidoras de la proliferacion del virus causante de la hepatitis tipo c (vhc), y sus aplicaciones.

Also Published As

Publication number Publication date
PT833902E (pt) 2003-09-30
ATE240392T1 (de) 2003-05-15
WO1996039500A2 (en) 1996-12-12
AU6221996A (en) 1996-12-24
EP0833902A2 (en) 1998-04-08
EP1331267A2 (en) 2003-07-30
CA2226438A1 (en) 1996-12-12
AR002757A1 (es) 1998-04-29
EP1331267A3 (en) 2003-12-03
ZA964446B (en) 1996-12-06
EP0833902B1 (en) 2003-05-14
WO1996039500A3 (en) 1997-03-13
DE69628167D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
ES2104717T3 (es) Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus.
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
DE69431485D1 (de) Doppelsträngige peptidenukleinsäuren
BR9206049A (pt) Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ES2066760T3 (es) Nucleotidos de alquinilamino.
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
ES2188760T3 (es) Oligonucleotidos especificos para el virus de la hepatitis b.
DK0409472T3 (da) Knoglemorfogenetisk protein
EP0630280A4 (en) METHOD AND DEVICE FOR REMOVING DNA, VIRUSES AND ENDOTOXINS.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE420190T1 (de) Rekombinanter lebendimpfstoff, der katzenherpesvirus typ i enthält, insbesondere für die behandlung von infektiöser bauchfellentzündung bei katzen
ES2108748T3 (es) Amplificacion de acidos nucleicos con actividad de rna polimerasa dependiente de dna, de rna replicasas.
BR0011033A (pt) Métodos de purificação de dna e dna purificado
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE69732029D1 (de) Dna enthaltende impfstoffen
ES2196157T3 (es) Oligonucleotidos especificos para el virus de la hepatitis c.
DE69632643D1 (de) Verwendungen von nukleinsäuren die ein retrovirus aus schweinen entnommen sind
ES2014546A6 (es) Procedimiento para la obtencion de fctor activador de neutrofilos.
EA200100700A1 (ru) Гены и белки и их применение
DE69728897D1 (de) Saeugetierchemokine
ES2182827T3 (es) Gen del virus corona canino y usos del mismo.
ATE285253T1 (de) Beta-interferon zur behandlung von immunerkrankungen